Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBio's revenue for the
six
months ended in Dec. 2025 was €1,618 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €2,143 Mil.
3SBio's Revenue per Share for the
six
months ended in Dec. 2025 was €0.65.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.87.
Good Sign:
3SBio Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of 3SBio was 101.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 39.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 22.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, 3SBio's highest 3-Year average Revenue per Share Growth Rate was 39.90% per year. The lowest was 7.50% per year. And the median was 14.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
3SBio Revenue Related Terms
3SBio Revenue Historical Data
* Premium members only.
The historical data trend for 3SBio's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 3SBio's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Revenue distribution charts can be found below:
* The bar in red indicates where 3SBio's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2,143 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (STU:83B) has a Revenue of €2,143 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on 3SBio and its competitors.
Is 3SBio's Revenue too high?
3SBio's current Revenue is €2,143 Mil. Overall, 3SBio has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Revenue compare to VRTX and REGN?
3SBio's Revenue of €2,143 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on 3SBio and its competitors. 3SBio's current Revenue is €2,143 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.39, compared to a current price of €1.78 — trading 28.1% above its estimated fair value. The current Revenue is €2,143 Mil. 3SBio's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For 3SBio (STU:83B), the current Revenue is €2,143 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.78 is trading 28.1% above its estimated GF Value™ of €1.39.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
Revenue: €2,143 Mil
GF Value™: €1.39 vs. price of €1.78 (28.1% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
88GF Score
Get the complete analysis for STU:83B
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
